参考文献/References:
[1] Hu B, Guo H, Zhou P, Shi ZL. Characteristics of SARS-CoV-2 and COVID-19[J]. Nat Rev Microbiol, 2020, 1-14.
[2] Kremer S, Lersy F, Anheim M, et al. Neurologic and neuroimaging findings in patients with COVID-19: A retrospective multicenter study[J]. Neurology, 2020, 95(13): e1868-e1882.
[3] Mao L, Jin H, Wang M, et al. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in wuhan, China[J]. JAMA Neurol, 2020, 77(6): 683-690.
[4] Frontera JA, Sabadia S, Lalchan R, et al. A prospective study of neurologic disorders in hospitalized COVID-19 patients in New York city[J]. Neurology, 2020: 10.1212/WNL.0000000000010979.
[5] Moriguchi T, Harii N, Goto J, et al. A first case of meningitis/encephalitis associated with SARS-Coronavirus-2[J]. Int J Infect Dis, 2020, 94: 55-58.
[6] Majidi S, Fifi JT, Ladner TR, et al. Emergent large vessel occlusion stroke during New York city’s COVID-19 outbreak: clinical characteristics and paraclinical findings[J]. Stroke, 2020, 51(9): 2656-2663.
[7] Lodigiani C, Iapichino G, Carenzo L, et al. Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy[J]. Thromb Res, 2020, 191: 9-14.
[8] Yaghi S, Ishida K, Torres J, et al. SARS2-CoV-2 and stroke in a New York healthcare system[J]. Stroke, 2020, 51(7): 2002-2011.
[9] Rothstein A, Oldridge O, Schwennesen H, et al. Acute cerebrovascular events in hospitalized COVID-19 patients[J]. Stroke, 2020, 51(9): e219-e222.
[10] Boehme AK, Luna J, Kulick E, et al. Influenza-like illness as a trigger for ischemic stroke[J]. Ann Clin Transl Neurol, 2018, 5(4): 456-463.
[11] Merkler AE, Parikh NS, Mir S, et al. Risk of ischemic stroke in patients with coronavirus disease 2019(COVID-19)vs patients with influenza[J]. JAMA Neurol, 2020, 77(11): 1-7.
[12] Katz JM, Libman RB, Wang JJ, et al. Cerebrovascular complications of COVID-19[J]. Stroke, 2020, 51(9): e227-e231.
[13] Ntaios G, Michel P, Georgiopoulos G, et al. Characteristics and outcomes in patients with COVID-19 and acute ischemic stroke: the global COVID-19 stroke registry[J]. Stroke, 2020, 51(9): e254-e258.
[14] Bhatia R, Pedapati R, Komakula S, et al. Stroke in coronavirus disease 2019: a systematic review[J]. J Stroke, 2020, 22(3): 324-335.
[15] Tan YK, Goh C, Leow A, et al. COVID-19 and ischemic stroke: a systematic review and meta-summary of the literature[J]. J Thromb Thrombolysis, 2020, 50(3): 587-595.
[16] Yc L, Bai WZ, Hashikawa T. The neuroinvasive potential of SARS-CoV2 May play a role in the respiratory failure of COVID-19 patients[J]. J Med Virol, 2020, 92(6): 552-555.
[17] Desforges M, Le CA, Dubeau P, et al. Human coronaviruses and other respiratory viruses: underestimated opportunistic pathogens of the central nervous system?[J]. Viruses, 2019, 12(1): 14.
[18] Markus H, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor[J]. Cell, 2020, 181(2): 271-280.e8.
[19] Buzhdygan TP, Deore BJ, Baldwin-Leclair A, et al. The SARS-CoV-2 spike protein alters barrier function in 2D static and 3D microfluidic in-vitro models of the human blood-brain barrier[J]. Neurobiol Dis, 2020, 146: 105131.
[20] Paniz-Mondolfi A, Bryce C, Grimes Z, et al. Central nervous system involvement by severe acute respiratory syndrome coronavirus-2(SARS-CoV-2)[J]. J Med Virol, 2020, 92(7): 699-702.
[21] Matschke J, Lütgehetmann M, Hagel C, et al. Neuropathology of patients with COVID-19 in Germany: a post-mortem case series[J]. Lancet Neurol, 2020, 19(11): 919-929.
[22] Varga Z, Flammer AJ, Steiger P, et al. Endothelial cell infection and endotheliitis in COVID-19[J]. Lancet, 2020, 395(1234): 1417-1418.
[23] Xu P, Sriramula S, Lazartigues E. ACE2/ANG-(1-7)/Mas pathway in the brain: the axis of good[J]. Am J Physiol Regul Integr Comp Physiol, 2011, 300(4): R804-R817.
[24] Monteil V, Kwon H, Prado P, et al. Inhibition of SARS-CoV-2 infections in engineered human tissues using Clinical-Grade soluble human ACE2[J]. Cell, 2020, 181(4): 905-913.e7.
[25] Hess DC, Eldahshan W, Rutkowski E. COVID-19-Related stroke[J]. Transl Stroke Res, 2020, 11(3): 322-325.
[26] Giannakopoulos B, Krilis SA. The pathogenesis of the antiphospholipid syndrome[J]. N Engl J Med, 2013, 368(11): 1033-1044.
[27] Beyrouti R, Adams ME, Benjamin L, et al. Characteristics of ischaemic stroke associated with COVID-19[J]. J Neurol Neurosurg Psychiatry, 2020, 91(8): 889-891.
[28] Zhang Y, Xiao M, Zhang S, et al. Coagulopathy and antiphospholipid antibodies in patients with covid-19[J]. N Engl J Med, 2020, 382(17): e38.
[29] Piazza G, Campia U, Hurwitz S, et al. Registry of arterial and venous thromboembolic complications in patients with COVID-19[J]. J Am Coll Cardiol, 2020, 76(18): 2060-2072.
[30] Ranucci M, Ballotta A, Di DU, et al. The procoagulant pattern of patients with COVID-19 acute respiratory distress syndrome[J]. J Thromb Haemost, 2020, 18(7): 1747-1751.
[31] Guo T, Fan Y, Chen M, et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019(COVID-19)[J]. JAMA Cardiol, 2020, 5(7): 811-818.
[32] Ranard LS, Fried JA, Abdalla M, et al. Approach to acute cardiovascular complications in COVID-19 infection[J]. Circ Heart Fail, 2020, 13(7): e007220.
[33] Mehta P, Mcauley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression[J]. Lancet, 2020, 395(1229): 1033-1034.
[34] Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China[J]. Lancet, 2020, 395(1223): 497-506.